Selected Grants
Study drug QTX3046 for KRAS G12D mutated advanced solid tumors
Clinical TrialPrincipal Investigator · Awarded by Quanta Therapeutics, Inc. · 2024 - 2029RMC-6236 + gemcitabine and nab-paclitaxel for pancreatic cancer (RMC-GI-102_C)
Clinical TrialPrincipal Investigator · Awarded by Revolution Medicines, Inc · 2024 - 2029RMC-6236 plus 5-flourouracil-based regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma- Subprotocol A
Clinical TrialPrincipal Investigator · Awarded by Revolution Medicines, Inc · 2024 - 2029Study of RMC-6236 in Combination with Cetuximab with or without mFOLFOX6 in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - Subprotocol B
Clinical TrialPrincipal Investigator · Awarded by Revolution Medicines, Inc · 2024 - 2029AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer (M24-
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2029Dabrafenib + trametinib in patients w/rare BRAF V600E mutated solid tumor (CDRB436IIC01)
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2029APL-5125 for advanced solid tumors (AP10CP01)
Clinical TrialPrincipal Investigator · Awarded by Apollo Therapeutics · 2024 - 2029A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 with Panitumumab in Patients with Advanced or Metastatic RAS mutant Colorectal and Pancreatic Ductal Cancers
Clinical TrialPrincipal Investigator · Awarded by MapKure, LLC · 2024 - 2029Study drug QTX3034 for patients with KRAS G12D solid tumors (QTX3034-001)
Clinical TrialPrincipal Investigator · Awarded by Quanta Therapeutics, Inc. · 2024 - 2029[ROMast-001] A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) (Master Rollover Study)
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2024 - 2029Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001)
Clinical TrialPrincipal Investigator · Awarded by Revolution Medicines, Inc · 2024 - 2029Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naive Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2024 - 20293T: A Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by Mayo Clinic - Rochester · 2023 - 2029Perioperative dostarlimab vs standard of care for resectable colon cancer (219606)
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2023 - 2028[M24-311] A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2023 - 2028[BP44474] A phase I, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of RO7589831 in participants with advanced solid tumors harboring microsatellite instability (MSI) and/or deficien
Clinical TrialPrincipal Investigator · Awarded by Roche TCRC, Inc · 2023 - 2028BGB-A317-LBL-007-201
Clinical TrialPrincipal Investigator · Awarded by BeiGene USA, Inc. · 2023 - 2028ABBV-400 for Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2023 - 2028[DEK-DKK1-P207] Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Clinical TrialPrincipal Investigator · Awarded by Leap Therapeutics, Inc. · 2022 - 2027Defining Actionable Opportunities in Malignant Phyllodes via Genomic Profiling
ResearchCollaborator · Awarded by Food and Drug Administration · 2024 - 2027An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (SGNT
Clinical TrialPrincipal Investigator · Awarded by Seagen, Inc · 2022 - 2027NCCN/Lilly Grant to Optimize Biomarker Driven Therapy in Lung and Thyroid Cancers
ResearchPrincipal Investigator · Awarded by National Comprehensive Cancer Network · 2024 - 2027A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER (INTRINSIC)
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2021 - 2026A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2023 - 2026A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Clinical TrialPrincipal Investigator · Awarded by Erasca, Inc · 2021 - 2026[DS8201-A-U207] A phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-overexpressing locally advanced, unresectable or metastatic colorectal cancer (Destiny-CRC02)
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2021 - 2026Daiichi Sankyo - Safety and Efficacy of U3-1402 in Subjects with Advanced or Metastatic Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2020 - 2025SGNTUC-024 Tucatinib plus trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2020 - 2025A Phase 1A/B Study To Evaluate The Safety And Tolerability Of ETC-1922159 In Advanced Solid Tumours
Clinical TrialPrincipal Investigator · Awarded by Experimental Drug Development Centre · 2020 - 2025PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy after Progression on Anti-EGFR Therapy in Patients with Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Clinical TrialPrincipal Investigator · Awarded by Academic and Community Cancer Research United · 2020 - 2025COLOMATE: COlorectal Cancer Liquid BiOpsy Screening Protocol for Molecularly Assigned ThErapy
Clinical TrialPrincipal Investigator · Awarded by Academic and Community Cancer Research United · 2019 - 2025Mountaineer-Phase ll (ACCRU)
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2019 - 2024A Multicenter Phase I/Ib open label dose escalation study of ABBV-399, and antibody drug conjugate, in subjects with advanced solid tumors.
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2014 - 2024A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors
Clinical TrialPrincipal Investigator · Awarded by Curegenix Inc. · 2019 - 2024A Phase 1/1b first-in-human dose escalation and expansion study for theevaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult
Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2019 - 2024A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2019 - 2024Investigational drug GB1275 in combo with standard therapy for certain metastatic GI cancers
Clinical TrialPrincipal Investigator · Awarded by Gossamer Bio · 2020 - 2023A PHASE Ib, MULTICENTER, OPEN-LABELSTUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABL
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2019 - 2023Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2014 - 2023A Multicenter phase 1/1b open label dose escalation study of ABT-165 a dual variable domain immunoglobin in subject with advanced solid tumors.
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2013 - 2023SGNTUC-022 Tucatinib, trastuzumab, ramucirumab, and paclitaxel versus paclitaxel and ramucirumab in previously treated HER2+ gastroesophageal cancer
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2020 - 2023Implementing Evidence-Based Interventions to Enhance Equity in Oncology Genomic Testing
ResearchCo Investigator · Awarded by V Foundation for Cancer Research · 2022 - 2023A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH NKTR-214 AND IN COMBINATION WITH NKTR-214 PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
Clinical TrialPrincipal Investigator · Awarded by Nektar Therapeutics · 2018 - 2023Mountaineer-Phase ll (ACCRU)
Clinical TrialPrincipal Investigator · Awarded by Academic and Community Cancer Research United · 2017 - 2023A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity ofABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) or its Ligands
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2018 - 2023Advancing Cancer Care in the Rural Southeast: Enhancing Precision Medicine and Institutional Collaboration in Community Cancer Centers
ResearchCollaborator · Awarded by V Foundation for Cancer Research · 2021 - 2023A phase I open label dose escalation and dose-expansion study to evaluate the safety toloerability pharmcokinetics immunogenicity and antitumor activate of Medi-9447 alone and in combination with MEDI
Clinical TrialPrincipal Investigator · Awarded by MedImmune, Inc. · 2015 - 2022Partnership to Support the Duke Molecular Tumor Board Program
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2020 - 2022SBT6050-101 A Phase 1/1b, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Expressing HER2
Clinical TrialPrincipal Investigator · Awarded by Silverback Therapeutics, Inc. · 2021 - 2022Phase Ib study of Atezolizumab in combination with Bevacizumab in solid tumor patients
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2017 - 2022Cabozantinib (XL184) with panitumamab in KRAS wild-type metastatic colorectal cancer with pharmacodynamic studies, XL184-IST28
Clinical TrialPrincipal Investigator · Awarded by Exelixis, Inc · 2014 - 2021Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2018 - 2021An open label multicenter dose escalation and expansion phase IB study to evaluste the safety pharmacokinetics and therapeutic activity
Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2016 - 2020A Multicenter, phase I open-label dose escalation study of ABBV-085 an antibody drug conjugated in subjects with advanced solid tumors.
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2016 - 2020A Phase 3 Randomized double blined placebo controlled study to evaluate the efficacy and safety of GS-5745 conbimed with mFOLFAX6 as first line treatment in patients with advanced gastric or gastroeso
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2020A two part phase I multicenter ipen label study of DKN-01 in combination with weekly paclitaxel; Arm A; A dose escalation study in patients with relapsed or refractory esophageal cancer or gastro esophageal junction tumors; Arm B: A
Clinical TrialPrincipal Investigator · Awarded by Leap Therapeutics, Inc. · 2014 - 2020A Phase 1, multicenter, open-label, dose-escalation study of SNF-2FF in patients with advanced solid tumors
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2017 - 2020A phase 1 first in human open labe dose escalation study of MGD007 a humanized gpA33 x CD3 dual affinity retargeted (DART) protein i patients with relapsed refractory metastatic colorectal carcinoma
Clinical TrialPrincipal Investigator · Awarded by MacroGenics, Inc. · 2014 - 2019AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T CELL BISPECIFIC ANTIBODY THAT TARGETS THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3
Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2018 - 2018A randomized double blinded placebo controlled phase III study of adjuvant Regorafenib versus placebo for patient with stage IV coloractal cancer after curative treatment of liver metastases.
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2013 - 2018A Phase 1a/b dose escalation study of the safety pharmacokinetics and pharmacodynamics of OMP-131-R10 in advanced solid tumors and in combination with FOLFIRI for patients with previously treated metastatic colorectal cancer.
Clinical TrialPrincipal Investigator · Awarded by OncoMed Pharmaceuticals · 2016 - 2018External Relationships
- AbbVie, Inc.
- Amgen, Inc.
- Astellas Pharma Inc.
- AstraZeneca
- Bayer
- BeiGene
- Bristol-Myers Squibb (BMS)
- Daiichi Sankyo Co., Ltd
- Eli Lilly & Co.
- GE Healthcare
- Genentech, Inc (Roche Holding)
- GlaxoSmithKline
- Incyte
- Ipsen
- Jazz Pharmaceuticals
- Johnson and Johnson
- Merck Sharp & Dohme Inc., One Merck Drive, Whitehouse Station, NJ 08889-0100.
- Natera
- Pfizer Inc.
- Quanta Therapeutics
- Regeneron Pharmaceuticals
- Sanofi
- Taiho
- Takeda Oncology
- Triumvira Immunologics
- Xilio Therapeutics
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.